Skip to main content
Figure 6 | Molecular Neurodegeneration

Figure 6

From: Nucleation of protein aggregation kinetics as a basis for genotype-phenotype correlations in polyglutamine diseases

Figure 6

Alternative therapeutic targets according to distinct subcellular loci. The slope (probability of nucleation at an individual repeat) and intercept (inversely related to the concentration of soluble mutant protein monomers) determines a critical number of the nucleus leading to polymerization pathway, considering as a threshold of polyQ cytotoxicity. Host defense factors (blue arrow) considerably inhibit the probability of nucleation in the cell nucleus. By contrast, the concentration of soluble mutant protein monomers in the cell nucleus is quite higher than the values in the cytoplasm. A rational therapeutic target (red arrow) is to reduce the concentration of soluble mutant protein monomers in the cell nucleus, and is to inhibit the probability of nucleation and reduce the concentration of soluble mutant protein monomers in the cytoplasm.

Back to article page

Molecular Neurodegeneration

ISSN: 1750-1326